These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 34544656)

  • 1. Epidermal growth factor receptor (EGFR) mutation testing is useful for primary lung cancer diagnosis and appropriate surgical resection: A case series.
    Kitamura A; Ishii K; Okafuji K; Kojima F; Bando T
    Respir Investig; 2022 Jan; 60(1):171-175. PubMed ID: 34544656
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epidermal Growth Factor Receptor Gene Mutation in Pleural Lavage Cytology Findings of Primary Lung Adenocarcinoma Cases.
    Inoue T; Matsumura Y; Araki O; Karube Y; Maeda S; Kobayashi S; Chida M
    Ann Thorac Cardiovasc Surg; 2018 Feb; 24(1):1-5. PubMed ID: 29093430
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Relationship between EGFR Mutations and Pathological Classification and 
Specimen of Lung Adenocarcinoma].
    Kang L; Zheng J; Zhu X
    Zhongguo Fei Ai Za Zhi; 2017 Jun; 20(6):382-388. PubMed ID: 28641695
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discrepancy of epidermal growth factor receptor mutation in lung adenocarcinoma presenting as multiple ground-glass opacities.
    Liu M; He WX; Song N; Yang Y; Zhang P; Jiang GN
    Eur J Cardiothorac Surg; 2016 Nov; 50(5):909-913. PubMed ID: 27032467
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of targeted next-generation sequencing with conventional sequencing for predicting the responsiveness to epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) therapy in never-smokers with lung adenocarcinoma.
    Han JY; Kim SH; Lee YS; Lee SY; Hwang JA; Kim JY; Yoon SJ; Lee GK
    Lung Cancer; 2014 Aug; 85(2):161-7. PubMed ID: 24857785
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Computed tomography and clinical features associated with epidermal growth factor receptor mutation status in stage I/II lung adenocarcinoma.
    Zou J; Lv T; Zhu S; Lu Z; Shen Q; Xia L; Wu J; Song Y; Liu H
    Thorac Cancer; 2017 May; 8(3):260-270. PubMed ID: 28383802
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The relationship between EGFR mutation status and clinic-pathologic features in pulmonary adenocarcinoma.
    Deng H; Liu J; Duan X; Liu Y
    Pathol Res Pract; 2018 Mar; 214(3):450-454. PubMed ID: 29496311
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Associations between clinical data and computed tomography features in patients with epidermal growth factor receptor mutations in lung adenocarcinoma.
    Cao Y; Xu H; Liao M; Qu Y; Xu L; Zhu D; Wang B; Tian S
    Int J Clin Oncol; 2018 Apr; 23(2):249-257. PubMed ID: 28988295
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correlation of EGFR mutation status with predominant histologic subtype of adenocarcinoma according to the new lung adenocarcinoma classification of the International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society.
    Villa C; Cagle PT; Johnson M; Patel JD; Yeldandi AV; Raj R; DeCamp MM; Raparia K
    Arch Pathol Lab Med; 2014 Oct; 138(10):1353-7. PubMed ID: 24571650
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epidermal growth factor receptor mutation status is strongly associated with smoking status in patients undergoing surgical resection for lung adenocarcinoma.
    Matsumura Y; Owada Y; Inoue T; Watanabe Y; Yamaura T; Fukuhara M; Muto S; Okabe N; Hasegawa T; Hoshino M; Osugi J; Higuchi M; Suzuki H
    Interact Cardiovasc Thorac Surg; 2017 Nov; 25(5):690-695. PubMed ID: 29049789
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Analysis of epidermal growth factor receptor mutations and its clinico-pathologic characteristics of the primary lung adenocarcinoma in Xinjiang Uighur Autonomous Region].
    Ma XM; Cao YZ; Ji WL; Zhao F; Fang XZ
    Beijing Da Xue Xue Bao Yi Xue Ban; 2016 Aug; 48(4):663-666. PubMed ID: 29263509
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical outcomes of EGFR-TKI treatment and genetic heterogeneity in lung adenocarcinoma patients with EGFR mutations on exons 19 and 21.
    Yu JY; Yu SF; Wang SH; Bai H; Zhao J; An TT; Duan JC; Wang J
    Chin J Cancer; 2016 Mar; 35():30. PubMed ID: 27001083
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of tissue type and content of neoplastic cells of samples on the quality of epidermal growth factor receptor mutation analysis among patients with lung adenocarcinoma.
    Paliogiannis P; Attene F; Cossu A; Defraia E; Porcu G; Carta A; Sotgiu MI; Pazzola A; Cordero L; Capelli F; Fadda GM; Ortu S; Sotgiu G; Palomba G; Sini MC; Palmieri G; Colombino M
    Mol Med Rep; 2015 Jul; 12(1):187-91. PubMed ID: 25683726
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of epidermal growth factor receptor gene expression level on clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients taking first-line epidermal growth factor receptor-tyrosine kinase inhibitors.
    Chang HC; Chen YM; Tseng CC; Huang KT; Wang CC; Chen YC; Lai CH; Fang WF; Kao HC; Lin MC
    Tumour Biol; 2017 Mar; 39(3):1010428317695939. PubMed ID: 28351317
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic value of EGFR mutations in surgically resected pathological stage I lung adenocarcinoma.
    Nishii T; Yokose T; Miyagi Y; Daigo Y; Isaka T; Furumoto H; Ito H; Murakami S; Kondo T; Saito H; Oshita F; Yamada K; Matsukuma S; Nakayama H; Masuda M
    Asia Pac J Clin Oncol; 2017 Oct; 13(5):e204-e211. PubMed ID: 27349355
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic Impact of EGFR Driver Mutations on Postoperative Disease Recurrence in Lung Adenocarcinoma.
    Okamoto T; Kitahara H; Shimamatsu S; Katsura M; Takada K; Fujishita T; Suzuki Y; Morodomi Y; Tagawa T; Maehara Y
    Anticancer Res; 2016 Jun; 36(6):3057-63. PubMed ID: 27272827
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cancer/testis antigen expression as a predictor for epidermal growth factor receptor mutation and prognosis in lung adenocarcinoma.
    Baba T; Shiota H; Kuroda K; Shigematsu Y; Ichiki Y; Uramoto H; Hanagiri T; Tanaka F
    Eur J Cardiothorac Surg; 2013 Apr; 43(4):759-64. PubMed ID: 22826471
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The usefulness of mutation-specific antibodies in detecting epidermal growth factor receptor mutations and in predicting response to tyrosine kinase inhibitor therapy in lung adenocarcinoma.
    Kozu Y; Tsuta K; Kohno T; Sekine I; Yoshida A; Watanabe S; Tamura T; Yokota J; Suzuki K; Asamura H; Furuta K; Tsuda H
    Lung Cancer; 2011 Jul; 73(1):45-50. PubMed ID: 21129809
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Retrospective analysis of icotinib neoadjuvant therapy of 63 lung cancer patients.
    Wang T; Liu Y; Zhou B; Hao S; Wang Z; Liang N; Liu J; Wang S
    Indian J Cancer; 2017; 54(1):215-222. PubMed ID: 29199694
    [TBL] [Abstract][Full Text] [Related]  

  • 20. EGFR mutation L747P led to gefitinib resistance and accelerated liver metastases in a Chinese patient with lung adenocarcinoma.
    Yu G; Xie X; Sun D; Geng J; Fu F; Zhang L; Wang H
    Int J Clin Exp Pathol; 2015; 8(7):8603-6. PubMed ID: 26339441
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.